NCT02830932View on ClinicalTrials.gov

Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f)

PHASE1CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

June 22, 2016

Primary Completion Date

September 16, 2016

Study Completion Date

September 20, 2017

Conditions
Respiratory Syncytial Virus (RSV)
Interventions
BIOLOGICAL

VXA-RSV-f Tablets (high dose)

The drug product will be provided as small white enteric-coated tablets. Multiple tablets may be administered to delivered the high dose.

OTHER

VXA Placebo Tablets

The placebo will be provided as small white enteric-coated tablets that are similar in size and number to the active drug product tablets.

BIOLOGICAL

VXA-RSV-f Tablets (low dose)

The drug product will be provided as small white enteric-coated tablets. Multiple tablets may be administered to delivered the low dose

Trial Locations (1)

32934

Optimal Research, Melbourne

Sponsors

Lead Sponsor

Vaxart
All Listed Sponsors
lead

Vaxart

INDUSTRY

NCT02830932 - Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f) | Biotech Hunter | Biotech Hunter